FibroBiologics
FBLG
16 hedge funds and large institutions have $270K invested in FibroBiologics in 2026 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 4 closing their positions.
87% more capital inflows, than outflows
Capital inflows: $154K | Capital outflows: $82.1K
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
0.81% less ownership
Funds ownership: 6.28% → 5.47% (-0.81%)
6% less funds holding
Funds holding: 17 → 16 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CFP
Cascade Financial Partners
San Diego,
California
|
+$107K |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$28.2K |
| 3 |
Barclays
London,
United Kingdom
|
+$8.41K |
| 4 |
Tower Research Capital (TRC)
New York
|
+$4.96K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
+$2.61K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
-$46.3K |
| 2 |
Renaissance Technologies
New York
|
-$21.1K |
| 3 |
BlackRock
New York
|
-$7.44K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$5.4K |
| 5 |
NewEdge Advisors
New Orleans,
Louisiana
|
-$1.11K |
FBLG Hedge Fund Activity: Q2 2026 in Review
16 of the 8,354 institutional investors tracked by Wall St. Rank reported a position in FibroBiologics (FBLG) for Q2 2026, worth a combined $270K — down 7.4% from $291K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of FBLG and 3 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 5 added.
The largest buyer was Cascade Financial Partners, adding an estimated $107K. The largest seller was Vanguard Capital Management, cutting an estimated $46.3K.
- 16 institutional investors held FibroBiologics (FBLG) as of Q2 2026, down from 17 in Q1 2026.
- Funds reported $270K of FibroBiologics stock for Q2 2026, down 7.4% quarter-over-quarter.
- 3 funds opened new FibroBiologics positions in Q2 2026 and 4 closed out, a net change of -1 holder.
- The largest FibroBiologics buyer in Q2 2026 was Cascade Financial Partners, an estimated $107K added.
- The largest FibroBiologics seller in Q2 2026 was Vanguard Capital Management, an estimated $46.3K sold.
Based on aggregated 13F filings for Q2 2026.